UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

September 6, 2006 (Date of earliest event reported)

LABORATORY CORPORATION OF **AMERICA HOLDINGS**

Registrant as Specified in its	Charter)
1-11353	13-3757370
(Commission	(I.R.S. Employer
File Number)	Identification No.)
	1-11353 (Commission

27215

(Zip Code)

336-229-1127

(Registrant's telephone number including area code)

358 SOUTH MAIN STREET, **BURLINGTON, NORTH CAROLINA**

(Address of principal executive offices)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01. Regulation FD Disclosure

On September 6, 2006, Laboratory Corporation of America[®] Holdings (LabCorp[®]) (NYSE: LH), announced that David P. King, Executive Vice President and Chief Operating Officer, Bradford T. Smith, Executive Vice President, Corporate Affairs, and William (Brad) Hayes, Executive Vice President and Chief Financial Officer, were scheduled to speak at the Thomas Weisel Partners Healthcare Conference in Boston, MA. LabCorp's presentation was Thursday, September 7, 2006 at 3:15 p.m. (Eastern Time).

Exhibits

99.1 Press Release dated September 6, 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

<u>Laboratory Corporation of America Holdings</u> (Registrant)

By: /s/Bradford T. Smith Bradford T. Smith, Executive Vice President and Secretary

Date: September 8, 2006

Exhibit 99.1

Laboratory Corporation of America® Holdings 358 South Main Street Burlington, NC 27215 Telephone:(336) 584-5171

<u>FOR IMMEDIATE RELEASE</u> Investor Contact: Scott Fleming - 336-436-4879 Media Contact: Pam Sherry - 336-436-4855 Shareholder Direct: (800)LAB-0401 Company Information: www.LabCorp.com

LABCORP IS SCHEDULED TO PRESENT AT THE THOMAS WEISEL PARTNERS HEALTHCARE CONFERENCE

Burlington, NC, September 6, 2006 — Laboratory Corporation of America[®] Holdings (LabCorp[®]) (NYSE: LH) today announced that David P. King, Executive Vice President and Chief Operating Officer, Bradford T. Smith, Executive Vice President, Corporate Affairs, and William (Brad) Hayes, Executive Vice President and Chief Financial Officer, were scheduled to speak at the Thomas Weisel Partners Healthcare Conference in Boston, MA. LabCorp's presentation was Thursday, September 7, 2006 at 3:15 p.m. (Eastern Time).

A live audio webcast of the presentation will be available via the Company Web site at <u>www.labcorp.com</u> and archived for replay.

About LabCorp

Laboratory Corporation of America® Holdings, a S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of \$3.3 billion in 2005, approximately 24,000 employees nationwide, and more than 220,000 clients, LabCorp offers clinical assays ranging from routine blood analyses to HIV and genomic testing. LabCorp combines its expertise in innovative clinical testing technology with its Centers of Excellence: The Center for Molecular Biology and Pathology, in Research Triangle Park, NC; National Genetics Institute, Inc. in Los Angeles, CA; ViroMed Laboratories, Inc. based in Minneapolis, MN; The Center for Esoteric Testing in Burlington, NC; DIANON Systems, Inc. based in Stratford, CT; US LABS based in Irvine, CA; and Esoterix and its Colorado Coagulation, Endocrine Sciences, and Cytometry Associates laboratories. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. To learn more about our growing organization, visit our Web site at: www.LabCorp.com.

Each of the above forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorp's financial results is included in the Company's Form 10-K for the year ended December 31, 2005, and subsequent SEC filings.